Federal Register / Vol. 76, No. 156 / Friday, August 12, 2011 / Notices 50223 

NICEATM–ICCVAM Web site (http:// 

iccvam.niehs.nih.gov). 

References 

WHO. 2010. Rabies vaccines: WHO 

Position paper. Weekly Epidemiological 

Record 85(32):309–320. 

Dated: August 3, 2011. 

John R. Bucher, 

Associate Director, National Toxicology 

Program. 

[FR Doc. 2011–20540 Filed 8–11–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice To Change Catalog of Federal 

Domestic Assistance (CFDA) Number 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: This notice provides public 

announcement of CDC’s intent to award 

two awards to eligible applicants of 

State or Territorial Public Health 

Newborn Bloodspot Screening 

Programs. These activities are proposed 

by the above-mentioned grantees in 

their FY 2011 applications submitted 

under funding opportunity CDC–RFA– 

EH11–001, ‘‘Program to Support New 

Implementation of State or Territorial 

Public Health Laboratory Capacity for 

Newborn Bloodspot Screening of Severe 

Combined Immune Deficiency (SCID) 

(U01), ’’ Catalog of Federal Domestic 

Assistance Number (CFDA): 93.070. 

Approximately $900,000 in funding will 

be awarded to the grantees for the 

implementation of newborn screening 

for SCID. 

Accordingly, CDC adds the following 

information to the previously published 

funding opportunity announcement of 

EH11–001: 

Authority: Authorized under Section 301 

of the Public Health Service Act, [42 U.S.C. 

241], as amended. 

CFDA #: 93.070 Environmental Public 

Health Emergency Response. 

Award Information 

Type of Award: New Competing 

Cooperative Agreement. 

Approximate Total Current Fiscal 

Year ACA Funding: $900,000. 

Anticipated Number of Awards: 2. 

Fiscal Year Funds: 2011. 

Anticipated Award Date: September 

1, 2011. 

Application Selection Process 

Funding will be awarded to 

applicants based on results from the 

peer review panel ranking 

recommendations. 

Funding Authority 

CDC will add the authority to that 

which is reflected in the published 

Funding Opportunity CDC–RFA–EH11– 

001. The revised funding authority 

language will read: 

—Authorized under Section 301 of the 

Public Health Service Act, [42 U.S.C. 

241], as amended. 

DATES: The effective date for this action 

is the date of publication of this Notice 

and remains in effect until the 

expiration of the project period of the 

funded applications. 

FOR FURTHER INFORMATION CONTACT: Beth 

Gardner, Extramural Team Lead, 

National Center for Environmental 

Health, Centers for Disease Control and 

Prevention, 4770 Buford Hwy., Atlanta, 

GA 30341, telephone (770) 488–0572, email Bgardner@cdc.gov. 

SUPPLEMENTARY INFORMATION: None. 

Dated: August 3, 2011. 

James Stephens, 

Director of the Office of Science Quality, 

Centers for Disease Control and Prevention. 

[FR Doc. 2011–20507 Filed 8–11–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 76 FR 47189–47190, 

dated August 4, 2011) is amended to 

reflect the reorganization of the Center 

for Global Health, Centers for Disease 

Control and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: After the title and functional 

statements for the Division of Global 

Disease Detection and Emergency 

Response (CWJ), insert the following: 

Global Immunization Division (CWK). 

The Global Immunization Division 

(GID) protects the health of Americans 

and global citizens by preventing 

disease, disability, and death worldwide 

from vaccine-preventable diseases. In 

carrying out its mission, GID: (1) 

Provides national leadership and 

coordination of the CGH efforts to 

eradicate polio, control or eliminate 

measles, strengthen routine 

immunization programs, introduce new 

and under-utilized vaccines, and 

promote safe injection practices, in 

collaboration with international 

organizations and CDC Centers/ 

Institute/Offices; (2) provides short- and 

long-term consultation and technical 

assistance to the WHO, UNICEF, and 

foreign countries involved in global 

immunization activities and participates 

in international advisory group 

meetings on immunization issues; (3) 

administers grants to WHO, Pan 

American Health Organization (PAHO), 

UNICEF, and other international 

partners as appropriate for the provision 

of technical, programmatic, and 

laboratory support, and vaccine 

procurement for initiatives to support 

global immunization targets; (4) designs 

and participates in international 

research, monitoring, and evaluation 

projects to increase the effectiveness of 

immunization strategies as may be 

developed; (5) develops strategies to 

improve the technical skills and 

problem-solving abilities of program 

managers and health care workers in 

other countries; (6) refines strategies 

developed for the eradication or control 

of vaccine-preventable diseases in the 

Western Hemisphere for 

implementation in other parts of the 

world; (7) assists other countries, WHO, 

and other partners to improve 

surveillance for polio, measles, and 

other vaccine preventable diseases 

(VPDs); (8) prepares articles based on 

findings for publication in international 

professional journals and presentation 

at international conferences; (9) 

collaborates with other countries, WHO, 

UNICEF, and advocacy groups to ensure 

the availability of sufficient funds to 

purchase an adequate supply of polio, 

measles, and other vaccines, and funds 

for technical support for use in 

eradication and control efforts; and (10) 

provides technical and operational 

leadership for CDC’s activities in 

support of the immunization initiatives 

such as Global Alliance for Vaccines 

and Immunization and the Global 

Immunization Vision and Strategies. 

Office of the Director (CWK1). (1) 

Provides leadership, management, and 

oversight for all division activities; (2) 

provides coordination of budgeting and 

liaison with CGH, and FMO on budget 

and spending; (3) provides coordination 

and oversight of the division’s 

mstockstill on DSK4VPTVN1PROD with NOTICES

50224 Federal Register / Vol. 76, No. 156 / Friday, August 12, 2011 / Notices 

personnel actions including liaison with 

CGH and CDC’s human resource office; 

(4) develops and promotes partnerships 

with other organizations to support 

global immunization activities; (5) 

liaises and coordinates with other CDC 

offices engaged in global immunization 

activities; (6) provides coordination and 

oversight of division research and 

scientific publications, and liaison with 

other CDC offices involved in scientific 

oversight; (7) provides coordination of 

the division communications activities 

including liaison with other CDC 

communications offices and those of our 

partner agencies; (8) represents CDC, 

CGH, and the division at global and 

national meetings and other fora for 

global immunization activities; and (9) 

provides oversight for all Embassy/ 

International Cooperative 

Administrative Supportive Services 

costs for the division’s field staff. 

Vaccine Preventable Disease 

Eradication and Elimination Branch 

(CWKB). (1) Plans, coordinates, and 

directs, in collaboration with partners, 

technical and programmatic activities to 

eradicate or eliminate/control targeted 

VPDS; (2) participates in developing 

and implements improvements to 

immunization services, surveillance, 

monitoring, evaluation, and data 

management program elements for 

targeted diseases; (3) manages teams 

that coordinate regional activities and 

provide guidance and support to the 

Vaccine Preventable Disease Eradication 

and Elimination Branch (VPDEEB) staff 

assigned in the European Region, 

Eastern Mediterranean Region, African 

Region, South East Asia Region, and 

Western Pacific Region WHO regions; 

(4) participates in multilateral 

collaborations with an extensive array of 

CDC and external partners engaged in 

VPD eradication and elimination 

including: participating countries, other 

CDC organizations, other U.S. 

Government organizations, international 

organizations including WHO, the 

United Nations Foundation, UNICEF, 

and the World Bank; nongovernmental, 

private sector organizations and vaccine 

producers, and international advisory 

committees; (5) provides subject-matter 

expertise, short- and long-term 

consultations, and coordinates 

epidemiology, surveillance, and 

laboratory activities for programs to 

eradicate and eliminate VPDs; (6) 

participates in operation research, 

monitoring and evaluation projects and 

studies to improve VPD eradication and 

control programs and prepares articles 

based on findings for publication in 

international professional journals and 

presentation at international 

conferences; (7) assists with outbreak 

investigations and emergency response 

activities; (8) provides technical 

management for grants and cooperatives 

agreements for vaccine procurement and 

for provision of technical, 

programmatic, and laboratory support. 

Strengthening Immunization Systems 

Branch (CWKC). (1) Develops and brings 

to routine operational level, in 

collaboration with partners, programs to 

deliver established, newly available, or 

under-utilized vaccines for diseases of 

global importance; (2) assesses the 

impact of immunization service delivery 

through surveillance, monitoring of 

vaccine coverage, and operations 

research; (3) develops, evaluates, and 

recommends improvements to 

strengthen routine immunization 

programs, including those related to 

laboratory-based and integrated 

surveillance systems; immunization 

coverage, economic evaluations and 

post-introduction evaluations; (4) 

provides subject-matter expertise and 

short- and long-term consultations; (5) 

participates in multilateral 

collaborations with an extensive array of 

CDC and external partners engaged in 

delivery of routine services, 

surveillance, and coverage monitoring 

of VPDs including: participating 

countries, other CDC organizations, 

other U.S. Government organizations, 

international organizations including 

WHO, the United Nations Foundation, 

UNICEF, and the World Bank; nongovernmental, private sector 

organizations and vaccine producers, 

and international advisory committees; 

(6) assists partner countries to build 

capacity in the areas of service delivery, 

surveillance, health information 

systems, data management, laboratory 

services and surveillance, and decisionmaking to achieve effective, efficient, 

and sustainable immunization 

programs; (7) manages and provides 

guidance and support for the GID PAHO 

team that coordinates PAHO regional 

activities; (8) evaluates, in collaboration 

with partners, projects that integrate 

non-vaccine interventions with routine 

immunization programs; (9) designs and 

participates in research, monitoring and 

evaluation projects and studies to 

improve existing and newly developing 

VPD control and eradication programs 

and prepares articles based on findings 

for publication in international 

professional journals and presentation 

at international conferences; (10) assists 

with outbreak investigations and 

emergency response activities. 

Delete in its entirety the functional 

statements for the Global Immunization 

Division (CVGC) within the National 

Center for Immunization and 

Respiratory Diseases (CVG). 

Dated: August 3, 2011. 

Carlton Duncan, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–20355 Filed 8–11–11; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–5502–N2] 

Medicare Program; Accountable Care 

Organization Accelerated Development 

Learning Sessions; Center for 

Medicare and Medicaid Innovation, 

September 15th and 16th, 2011 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces the 

date and location of the second in a 

series of public educational sessions 

hosted by the Centers for Medicare & 

Medicaid Services (CMS). This two-day 

training session is the second 

Accelerated Development Learning 

Session (ADLS) hosted by CMS to help 

Accountable Care Organizations (ACOs) 

deliver better care and reduce costs. We 

invite all new or existing ACO entities 

to register a team of senior executives to 

attend the in-person ADLS. The ADLS 

will provide executives with the 

opportunity to learn about core 

functions of an ACO and ways to build 

their organization’s capacity to succeed 

as an ACO. 

DATES: Meeting Date: Thursday, 

September 15, 2011, 8 a.m to 5 pm., 

pacific daylight time (p.d.t): Friday, 

September 16, 2011, 8 a.m. to 5 p.m. 

(p.d.t). 

Deadline for Meeting Registration: 

Registration for the second ADLS will 

remain open until capacity has been 

reached for the September 15 through 

16 in-person meeting. Space is limited 

and participants are encouraged to 

register as soon as possible. 

ADDRESSES: Meeting Location: The 

second ADLS will be held at the Hyatt 

Regency San Francisco Airport at 1333 

Bayshore Highway, Burlingame, CA 

94010. Participants are responsible for 

their own travel, parking, meals, and 

overnight stay expenses. More 

information about the venue and 

accommodations can be found at 

https://acoregister.rti.org/. Potential 

participants are also strongly 

mstockstill on DSK4VPTVN1PROD with NOTICES